12 Month Price Forecast For ACHL
Distance to ACHL Price Forecasts
ACHL Price Momentum
🤔 Considering Achilles (ACHL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 1:43 PM UTC
ACHL Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, ACHL has a consensus that is bullish. The median price target is $0.00, with forecasts ranging from $0.00 to $0.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With ACHL currently trading at $1.15, the median price forecast suggests a -100.0% downside. The most optimistic forecast comes from at , projecting a -100.0% downside, while at provides the most conservative target, suggesting a -100.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACHL Analyst Consensus
ACHL Price Target Range
Latest ACHL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACHL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 5, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $6.00 |
| Apr 5, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $2.00 |
| Dec 14, 2023 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $0.50 |
| Aug 7, 2023 | Chardan Capital | Geulah Livshits | Buy | Reiterates | $11.00 |
| May 11, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $11.00 |
| Dec 7, 2022 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $8.00 |
| Dec 7, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Apr 26, 2021 | Chardan Capital | Geulah Livshits | Buy | Initiates | $27.00 |
| Apr 26, 2021 | B of A Securities | Buy | Initiates | $20.00 | |
| Apr 26, 2021 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $25.00 |
| Apr 26, 2021 | Oppenheimer | Mark Breidenbach | Outperform | Initiates | $23.00 |
| Apr 26, 2021 | JP Morgan | Eric Joseph | Underweight | Initiates | $11.00 |
Stocks Similar to Achilles Therapeutics plc
The following stocks are similar to Achilles based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Achilles Therapeutics plc (ACHL) Financial Data
Achilles Therapeutics plc has a market capitalization of $43.57M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Achilles Therapeutics plc (ACHL) Company Overview
About Achilles Therapeutics plc
Develops precision T cell therapies for cancer.
The company utilizes its proprietary AI-powered bioinformatics platform, PELEUS, to identify clonal neoantigens that are crucial for developing targeted therapies. Achilles Therapeutics generates revenue through the advancement of its clinical candidates, like CHIRON and THETIS, which are in clinical trials for treating specific types of solid tumors.
Founded in 2016 and headquartered in London, Achilles Therapeutics was previously known as Achilles TX Limited before rebranding in February 2021. The company focuses on innovative therapies for advanced non-small cell lung cancer and metastatic melanoma, aiming to improve patient outcomes through precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
204
CEO
Dr. Iraj Ali Ph.D.
Country
United Kingdom
IPO Year
2020
Website
www.achillestx.comAchilles Therapeutics plc (ACHL) Latest News & Analysis
AstraZeneca will receive proprietary data and samples from the TRACERx and Achilles' Material Acquisition Platform (MAP) as part of a transaction.
The transfer of proprietary data and samples to AstraZeneca could enhance its drug development capabilities, potentially leading to new therapies and improved market positioning, impacting stock performance.
Achilles Therapeutics plc (NASDAQ: ACHL) will transfer its American Depositary Shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024.
The transfer to the Nasdaq Capital Market may signal financial instability or lower growth prospects for Achilles Therapeutics, potentially impacting investor confidence and stock valuation.
As of September 30, 2024, the company reported a cash position of $86.1 million, excluding a $12.8 million R&D tax credit received in October 2024.
A strong cash position of $86.1 million indicates financial stability and potential for growth, while the upcoming R&D tax credit enhances liquidity and supports future investments.
Achilles Therapeutics PLC (ACHL) and Butterfly Network, Inc. (BFLY) have been compared to their sector's performance for the current year. Specific performance details were not provided.
The performance of ACHL and BFLY relative to their sector indicates their competitiveness and potential for growth, impacting investment decisions and portfolio strategies.
Achilles Therapeutics Announces Strategic Update
4 months agoAchilles Therapeutics has halted development of its TIL-based cNeT therapy and closed the Phase I/IIa CHIRON and THETIS trials. The company reported a cash position of $95.1 million as of June 30, 2024.
The discontinuation of the TIL-based cNeT therapy and trials signals a setback for Achilles, potentially impacting future growth and investor confidence amid strategic financial restructuring.
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
5 months agoAchilles announced a research collaboration with Arcturus Therapeutics to develop second-generation mRNA cancer vaccines utilizing AI-powered, tumor-targeting technology.
The collaboration could lead to innovative cancer treatments, potentially increasing market competitiveness and driving future revenue growth for Achilles.
Frequently Asked Questions About ACHL Stock
What is Achilles Therapeutics plc's (ACHL) stock forecast for 2025?
Analyst forecasts for Achilles Therapeutics plc (ACHL) are not currently available. The stock is trading at $1.15.
Is ACHL stock a good investment in 2025?
According to current analyst ratings, ACHL has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ACHL stock?
Price predictions from Wall Street analysts for ACHL are not currently available. The stock is trading at $1.15.
What is Achilles Therapeutics plc's business model?
The company utilizes its proprietary AI-powered bioinformatics platform, PELEUS, to identify clonal neoantigens that are crucial for developing targeted therapies. Achilles Therapeutics generates revenue through the advancement of its clinical candidates, like CHIRON and THETIS, which are in clinical trials for treating specific types of solid tumors.
What is the highest forecasted price for ACHL Achilles Therapeutics plc?
Price targets from Wall Street analysts for ACHL are not currently available. The stock is trading at $1.15.
What is the lowest forecasted price for ACHL Achilles Therapeutics plc?
Price targets from Wall Street analysts for ACHL are not currently available. The stock is trading at $1.15.
What is the overall ACHL consensus from analysts for Achilles Therapeutics plc?
The overall analyst consensus for ACHL is bullish. Out of 6 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are ACHL stock price projections?
Stock price projections, including those for Achilles Therapeutics plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
